Posluma Approved for PET Imaging in Prostate Cancer
Flotufolastat fluorine-18 (Posluma), a new PSMA-targeted PET radiopharmaceutical, has been approved in the US for use in prostate cancer.
Medscape Medical News
source https://www.medscape.com/viewarticle/992577?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/992577?src=rss
Comments
Post a Comment